Aranesp

Type: Product
Name: Aranesp
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Panel votes against painkiller

But demand for Enbrel and Aranesp slipped.The candidate would be the first to put oxycodone and morphine in one capsule.AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients ... [Published Medical Marketing And Media - 11 hours ago]
Entities: anodyne, Aranesp, Enbrel
First reported 20 hours ago - Updated 17 hours ago - 1 reports

Should Amgen join the biopharma breakup party? Analyst says maybe

Now that the Big Pharma breakup craze has moved down the drugmaker food chain to Baxter International, should Big Biotech jump on the trend? Maybe one in that group should, an analyst suggests. And as Forbes notes, analyst suggestions helped pressure ... [Published FiercePharma - 20 hours ago]
First reported Apr 22 2014 - Updated 21 hours ago - 1 reports

New Drugs Help Drive Amgen's Operating Income Up 18% in Q1

It was steady as she goes for one of the most decorated biopharmaceuticals in the U.S., Amgen ( NASDAQ: AMGN     ) , which reported solid top- and bottom-line growth in the first quarter following its acquisition of Onyx Pharmaceuticals, which closed ... [Published Motley Fool Discussion Boards - Apr 22 2014]
First reported Apr 23 2014 - Updated Apr 23 2014 - 1 reports

Amgen's CEO Discusses Q1 2014 Results - Earnings Call Transcript

Amgen, Inc. ( AMGN ) Q1 2014 Results Earnings Conference Call April 22, 2014 5:15 PM ETOperatorMy name is Marvin, and I’ll be your conference facilitator today for Amgen’s First Quarter Earnings Conference Call. All lines have been placed on mute to ... [Published Seeking Alpha - Apr 23 2014]
First reported Apr 22 2014 - Updated Apr 23 2014 - 1 reports

Amgen Profit Falls 25%

Amgen Inc (AMGN: Quote) on Tuesday reported a 25 percent decline in first-quarter profit, hurt mostly by tax and other expenses that offset a seven percent growth in revenues, with results falling short of Wall Street estimates.Going forward, the biotechnology ... [Published RTTNews.com - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Will Amgen (AMGN) Miss This Earnings Season? - Analyst Blog

Amgen Inc. (NASDAQ: AMGN[1]) is set to report first quarter 2014 results on Apr 22 after the market closes. Last quarter, the company had posted an earnings surprise of +10.37%. Let's see how things are shaping up for this announcement. Factors at Play ... [Published DailyMe.Com - Apr 22 2014]
Entities: Amgen Inc, XGEVA, Aranesp
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion

2014 Revenue and Adjusted EPS Guidance ReaffirmedTHOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2014. Key results include:Total revenues increased 7 percent to $4,521 ... [Published FiercePharma - Apr 22 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Will Amgen (AMGN) Miss This Earnings Season? - Analyst Blog

Amgen Inc. (NASDAQ: AMGN) is set to report first quarter 2014 results on Apr 22 after the market closes. Last quarter, the company had posted an earnings surprise of +10.37%. Let's see how things are shaping up for this announcement.Factors at PlayWhile ... [Published Benzinga.com - Apr 22 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 First Quarter Financial Results

/PRNewswire/ — Amgen (AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and ... [Published Jutia Group - Apr 17 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Incorporation of Ortho- and Meta-Tyrosine Into Cellular Proteins Leads to Erythropoietin-Resistance in an Erythroid Cell Line

ReferencesRossert J, Gassmann-Mayer C, Frei D, McClellan W: Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007;22:794-800.Bamgbola O: Resistance to erythropoietin-stimulating agents: ... [Published Sexual Development - Apr 14 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

Dege & Wagner get years of suspension & fines

As was first reported in Harnesslink.com last August, two trainers have plea bargained with the Pennsylvania Harness Racing Commission (PHRC) to minor benefits and still will be suspened for years from racing along with some stiff money fines.The PHRC ... [Published Harnesslink - Apr 05 2014]
First reported Apr 02 2014 - Updated Apr 03 2014 - 1 reports

Kyowa HK Applies For Additional Indication Of NESP In Japan

By Estel Grace MasangkayKyowa Hakko Kirin announced that is seeking approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) for additional indication of NESP Injection Plastic Syringe (NESP) for anemia with myelodysplastic syndrome.NESP ... [Published Pharmaceutical Online - Apr 02 2014]

Quotes

"Such divergent growth profiles for the different parts of Amgen means that any positive news from pipeline drugs ... may not offer the same upside sitting inside the slow-growing shell as it would in a smaller, more speculative company attractive to growth investors" Porges says (as quoted by Forbes)
"Strong underlying demand for our products and growth in adjusted operating income make us confident in our full-year growth outlook," Bradway said. "We continue to advance our robust late stage pipeline and expect to submit global filings for evolocumab in 2014."
"A number of enzymes involved in glycosylation utilize divalent cations as co-factors. For example, numerous enzymes involved in the dolichol-linked oligosaccharide synthesis require divalent cations as co-factors for activity (Couto et al. 1984 J Biol. Chem. 259(1):378-382; Jensen and Schutzbach 1981 J Biol. Chem. 256(24):12899-12904; Sharma et al. 1982 European Journal of Biochemistry 126(2):319-25). The enzyme which catalyses the addition of O-linked carbohydrate to the polypeptide also requires a divalent cation for activity (Sugiura et al. 1982 J Biol. Chem. 257(16):9501-9507). Manganese (Mn++) is a required co-factor for the enzyme .beta.-galactoside-.alpha.-1,3,-galactosyltransferase, which catalyzes the addition of terminal galactose to elongating N-acetyl-glucosamine sugars (Witsell et al. 1990 J Biol. Chem. 265(26):15731-7). It was previously reported that manganese at a concentration of 0.1 mM or 1 mM partially reversed the reduction in N-linked and O-linked occupancy of erythropoietin caused by A23187, a compound which depletes divalent cations (Kaufman et al. 1994 Biochemistry 33(33):9813-9)."

More Content

All (26) | News (25) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Panel votes against painkiller [Published Medical Marketing And Media - 11 hours ago]
Should Amgen join the biopharma breakup party? ... [Published FiercePharma - 20 hours ago]
Amgen's Q1 Earnings Decline Y/Y [Published Zacks.com - 23 hours ago]
Amgen's $4.5B in Q1 sales lags estimates, thank... [Published FiercePharma - Apr 23 2014]
Amgen's CEO Discusses Q1 2014 Results - Earning... [Published Seeking Alpha - Apr 23 2014]
New Drugs Help Drive Amgen's Operating Income U... [Published Motley Fool Discussion Boards - Apr 22 2014]
Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s... [Published Jutia Group - Apr 22 2014]
Amgen's First Quarter 2014 Revenues Increased 7... [Published FiercePharma - Apr 22 2014]
Amgen Profit Falls 25% [Published RTTNews.com - Apr 22 2014]
Will Amgen (AMGN) Miss This Earnings Season? - ... [Published DailyMe.Com - Apr 22 2014]
Will Amgen (AMGN) Miss This Earnings Season? - ... [Published Benzinga.com - Apr 22 2014]
Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen A... [Published Jutia Group - Apr 17 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 16 2014]
Incorporation of Ortho- and Meta-Tyrosine Into ... [Published Sexual Development - Apr 14 2014]
Researchers Submit Patent Application, "Product... [Published 4 Traders - Apr 10 2014]
Dege & Wagner get years of suspension & fines [Published Harnesslink - Apr 05 2014]
Kyowa HK Applies For Additional Indication Of N... [Published Pharmaceutical Online - Apr 02 2014]
Vitamin C [Published LewRockwell.com - Mar 27 2014]
The Protective Effects of Erythropoietin on Rat... [Published Sexual Development - Mar 24 2014]
Amgen net rises by 30% to $1,021 mn in Q4 [Published PharmaBiz - Jan 30 2014]
Methods and compositions for targeting agents i... [Published PharmCast - Jan 05 2014]
The Street Can't Help but Love Amgen [Published The Street Latest - Nov 12 2013]
The Corporate Whistleblower Center Now Urges Lo... [Published PRWeb - Oct 16 2013]
Amgen accused of improper marketing practices [Published Topnews.in - Dec 19 2012]
Amgen commits to two more years as Tour of Cali... [Published Velonation - Aug 05 2011]
Secrecy Surrounds the Development of Tests to D... [Published Genetic Engineering News - Aug 04 2011]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Apr 16 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.